Sanofi - ADR (SNY): Price and Financial Metrics

Sanofi - ADR (SNY): $48.70

0.30 (-0.61%)

POWR Rating

Component Grades








SNY Price/Volume Stats

Current price $48.70 52-week high $55.72
Prev. close $49.00 52-week low $42.63
Day low $48.44 Volume 1,196,754
Day high $48.85 Avg. volume 1,985,523
50-day MA $48.27 Dividend yield 3.05%
200-day MA $49.60 Market Cap 123.19B

SNY Stock Price Chart Interactive Chart >

Sanofi - ADR (SNY) Company Bio

Sanofi researches, develops, manufactures, and markets various therapeutic solutions. The company operates in three segments: Pharmaceuticals, Vaccines, and Animal Health. The company was founded in 1973 and is based in Paris, France.

SNY Latest News Stream

Event/Time News Detail
Loading, please wait...

SNY Latest Social Stream

Loading social stream, please wait...

View Full SNY Social Stream

Latest SNY News From Around the Web

Below are the latest news stories about SANOFI that investors may wish to consider to help them evaluate SNY as an investment opportunity.

15 Undervalued Defensive Stocks For 2024

In this article, we discuss the 15 undervalued defensive stocks for 2024. To skip the detailed overview of the market and defensive stocks, go directly to the 5 Undervalued Defensive Stocks For 2024. Defensive stocks are shares of companies that remain relatively stable during economic downturns as opposed to cyclical stocks. Defensive stocks usually outperform […]

Yahoo | December 24, 2023

Sanofi (SNY) Discontinues Tusamitamab Ravtansine Cancer Program

Sanofi (SNY) stops the development of tusamitamab ravtansine after a phase III study on the candidate for second-line metastatic non-small cell lung cancer fails to meet the primary endpoint.

Yahoo | December 22, 2023

Pharma Stock Roundup: FDA Nod to AZN's Eplontersen, CRL to MRK's Cough Candidate

FDA approves AstraZeneca (AZN) and Ionis' (IONS) Wainua (eplontersen) for ATTRv-PN and gives CRL to Merck's chronic cough candidate, gefapixant.

Yahoo | December 22, 2023

Sanofi scraps a top ADC prospect after study setback

The drug, acquired via a deal with ImmunoGen, was the most advanced experimental medicine in the French pharma’s pipeline.

Yahoo | December 21, 2023

Press Release: Sanofi announces end of program evaluating tusamitamab ravtansine after a 2L NSCLC Phase 3 trial did not meet a primary endpoint

Sanofi announces end of program evaluating tusamitamab ravtansine after a 2L NSCLC Phase 3 trial did not meet a primary endpoint CARMEN-LC03 trial did not meet dual primary endpoint of improving progression-free survival; tusamitamab ravtansine clinical development program will be discontinuedSanofi reinforces commitment to broader oncology development program including CEACAM5-directed antibody drug conjugates (ADC) with additional anticipated trials PARIS, December 21, 2023. Sanofi is disconti

Yahoo | December 21, 2023

Read More 'SNY' Stories Here

SNY Price Returns

1-mo 7.66%
3-mo 2.89%
6-mo 6.36%
1-year -2.02%
3-year -1.74%
5-year 31.32%
YTD 0.91%
2023 5.45%
2022 -1.00%
2021 5.87%
2020 -0.83%
2019 23.73%

SNY Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full SNY Dividend History

Continue Researching SNY

Want to see what other sources are saying about Sanofi's financials and stock price? Try the links below:

Sanofi (SNY) Stock Price | Nasdaq
Sanofi (SNY) Stock Quote, History and News - Yahoo Finance
Sanofi (SNY) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!